Bio Implant Allograft and Xenograft Market Report 2025

The bio implant allograft and xenograft market size has grown strongly in recent years. It will grow from $2.44 billion in 2024 to $2.66 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth during the historic period is linked to increasing demand for organ and tissue transplants, rising prevalence of chronic orthopedic conditions, growing awareness of advanced grafting procedures, expansion of surgical applications in dental and cardiovascular care, and greater adoption of trauma and reconstructive surgeries.

The bio implant allograft and xenograft market size is expected to see strong growth in the next few years. It will grow to $3.72 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth projected for the forecast period is driven by a growing preference for minimally invasive grafting techniques, increasing use in regenerative medicine, rising demand for customized and patient-specific graft solutions, expansion of healthcare infrastructure in emerging regions, and greater utilization in complex multi-tissue surgeries. Primary trends during the forecast period include technological advancements in graft preservation, innovations in decellularization and sterilization techniques, development of bioengineered composite grafts, advances in 3D printing for graft scaffolds, and improvements in cold storage and cryopreservation methods.

The increasing number of orthopedic surgeries is expected to drive growth in the bioimplant allograft and xenograft market in the near future. Orthopedic surgeries involve diagnosing, treating, correcting, and preventing conditions and injuries related to the musculoskeletal system, including bones, joints, ligaments, tendons, muscles, and nerves. The rise in these surgeries is largely due to the aging population, as older individuals are more susceptible to bone and joint disorders such as arthritis and fractures. Bioimplant allografts and xenografts support orthopedic surgeries by providing bone graft options that promote healing, enhance graft integration, and aid tissue regeneration. These grafts help reduce surgical complications by offering osteoconductive and osteoinductive benefits, ultimately improving patient recovery and outcomes. For example, in December 2023, the Health Security Agency, a government body in the UK, reported 102,025 orthopedic surgery procedures submitted for mandatory surveillance during 2022 to 2023, representing a 10.2 percent increase from 92,608 procedures recorded in 2021 to 2022. Consequently, the rising volume of orthopedic surgeries is fueling growth in the bioimplant allograft and xenograft market.

Key players in the bioimplant allograft and xenograft market are concentrating on developing innovative products such as demineralized bone allograft implants designed to boost osteoconductivity, improve graft integration, and speed up bone regeneration. Demineralized bone allograft implants are donor bone grafts from which minerals have been removed while retaining collagen and growth factors that encourage new bone formation and integration in orthopedic, spinal, and dental procedures. For instance, in February 2024, Tetrous Inc., a regenerative medicine company based in the United States, launched EnFix TAC, a fully demineralized bone allograft implant intended to complement its existing EnFix RC implant for rotator cuff surgery. The EnFix TAC focuses on healing at the tendon-to-bone interface, where traditional surgeries often lead to scar tissue and high failure rates. This implant delivers osteoinductive and osteoconductive effects through proprietary demineralized bone fibers and is offered in two configurations to accommodate various rotator cuff tear sizes.

In May 2022, Envista Holdings Corporation, a dental implant provider headquartered in the United States, acquired Osteogenics Biomedical Inc. for an undisclosed sum. This acquisition aims to strengthen Envista’s regenerative biomaterials portfolio and offer dental professionals a wide range of advanced bone grafting solutions by utilizing Osteogenics’ expertise in allografts, xenografts, and membranes. Osteogenics Biomedical Inc. is a US-based company specializing in the development of allograft and xenograft bone grafts, membranes, and wound care products for dental and surgical use.

Major players in the bio implant allograft and xenograft market are Medtronic plc, Stryker Corporation, Zimmer Biomet Holdings Inc., Charles River Laboratories International Inc., Arthrex Inc., Institut Straumann AG, Integra LifeSciences, NuVasive Inc., Bioventus Inc., Orthofix Medical Inc., MTF Biologics, BioHorizons Inc., MiMedx Group Inc., RTI Surgical Holdings Inc., LifeNet Health, AxoGen Inc., AlloSource, Xtant Medical Holdings Inc., Alpha Bio Tec, Geistlich Pharma AG.

North America was the largest region in the bio implant allograft and xenograft market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bio implant allograft and xenograft report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the bio implant allograft and xenograft market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Bioimplant allograft refers to a biologically derived graft obtained from a human donor, used to replace or repair damaged tissues in another individual. It supports tissue regeneration, promotes healing, and helps restore structural integrity. Xenograft refers to tissue sourced from a different species, such as porcine or bovine, which is carefully processed to ensure biocompatibility and safety before implantation in humans. It is used for tissue repair, wound healing, or surgical reconstruction when human donor material is limited.

The primary product types of bioimplant allograft and xenograft include allografts, xenografts, and composite grafts. Allografts are tissues transplanted from a human donor to another human recipient. They are available in various storage forms, including freeze-dried (lyophilized), fresh, and preserved tissue, and are distributed through direct sales, third-party distributors, and online platforms. Applications include orthopedic surgery, dental surgery, cardiovascular procedures, plastic and reconstructive surgery, and trauma surgery. End users include hospitals, ambulatory surgical centers, specialty clinics, and research and academic institutes.

The bio implant allograft and xenograft market research report is one of a series of new reports that provides bio implant allograft and xenograft market statistics, including bio implant allograft and xenograft industry global market size, regional shares, competitors with a bio implant allograft and xenograft market share, detailed bio implant allograft and xenograft market segments, market trends and opportunities, and any further data you may need to thrive in the bio implant allograft and xenograft industry. This bio implant allograft and xenograft market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bio implant allograft and xenograft market consists of sales of tendon grafts, cartilage grafts, skin grafts, meniscus grafts, and vascular grafts. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.